In the Spotlight...
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency
Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
Previous Digests
Tracking the neoantigen landscape in response to checkpoint blockade
October 16, 2024
While it is known that neoantigen immunoediting plays a role in immune checkpoint blockade (ICB) efficacy, it is unclear how neoantigen recognition by T cells impacts tumor presentation of antigens in response to ICB. Alban and Riaz et al...
A type 2 cytokine fusion with type 1 effects – using IL-4 to enhance antitumor immunity
October 9, 2024
Interleukin 4 (IL-4), a cytokine typically associated with humoral (type 2) immune responses, has recently been shown to promote survival in T and B cells. Studying whether IL-4 could be exploited to enhance cancer immunotherapy, Feng and Bai et...
Unmasking higher immunotherapy efficacy potential with a new IL-2 therapy
October 2, 2024
Attempts to avoid systemic toxicity and Treg activation induced by IL-2-directed therapy has resulted in the development of various engineered immunotherapy products that specifically target IL-2Rβ/γ on CD8+ T cells and NK cells. However, these products have, so far...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Lespinasse-Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
Current Sponsors
